Regulation of transcription from the oncogene c-myc has an important role in the genesis of various tumors. Therefore, c-myc is a potential target for chemotherapy by drugs which are able to modify its activity directly. In this article, we identify the binding sites in the P1 and P2 promoter regions of c-myc for the intercalating antibiotics actinomycin D and elsamicin A. Gel retardation experiments indicate that actinomycin D or elsamicin A binding can inhibit the formation of several DNA-protein complexes. However, relatively low concentrations of elsamicin A, but not actinomycin D, appear to increase the level of binding to the P1 promoter of a protein factor. Using pure Sp1 transcription factor and an oligonucleotide containing the Sp1 putative binding site, we determined that the binding enhancement induced by small amounts of elsamicin was on the Sp1-DNA complex. Run-off transcription experiments in vitro showed that the effect of elsamicin A on Sp1 binding is followed by the maintenance or a relative rise in transcription levels from the P1 promoter of c-myc, while actinomycin D always inhibited the transcription from the P1 c-myc promoter in a concentration-dependent manner. Higher concentrations of elsamicin acted as an inhibitor of the transcription from the P1 start site but not from the P2.
The control of c-myc expression appears to be essential for therapeutic action through their interaction with the c-myc oncogene [17Ϫ19] . In order to identify the mechanism by which normal cellular proliferation, and its failure may lead to the genesis of various tumours [1Ϫ5] . Transcription of the c-myc gene some drugs inhibit the expression of the c-myc gene, we analyzed the binding of actinomycin D and elsamicin A within the is initiated from two major start sites termed P1 and P2, which are located 161 bp apart in the human gene [1, 2] . In normal region Ϫ101 to ϩ212 of the human c-myc promoter region. We found that the presence of intercalating drugs can modulate the and resting cells P2 is the pivotal promoter producing up to 90% of the c-myc mRNA, while P1 provides up to 25% of c-myc binding of several protein factors to the P1 and P2 promoter regions, especially the Sp1 trans-acting factor, which also recogtranscripts in normal cells, but may predominate in malignant cells [1Ϫ3] . Regulation has been shown to occur at multiple nizes a consensus GϩC-rich tract in DNA [20] . We have also identified the binding sites for these drugs in the promoters, and levels and several positive and negative cis-acting elements within a 2.3-kb region upstream of the promoters coordinate the show that certain discrete DNA-protein complexes behave differentially in the presence of either actinomycin D or elsamicin c-myc expression in response to various physiological stimuli [1, A since some complexes are blocked by the presence of either 6, 7] . P1 and P2 appear to be regulated by a combination of drug, while others seem to be insensitive, or even somewhat positive and negative trans-acting factors binding within this reenhanced by the drugs. In general, impedence of the formation gion.
of DNA-protein complexes by the intercalating drugs produces The antitumor antibiotics actinomycin D (dactinomycin) and the inhibition of c-myc promoter transcription in vitro, though elsamicin A (elsamitrucin) [8, 9] are two DNA-binding drugs P1 and P2 are differentially sensitive to the presence of drug which intercalate preferentially into GϩC-rich steps [10Ϫ14], concentrations. and they are able to inhibit the transcription in vitro from prokaryotic and phage genes [15, 16] . However, there is an increasing need to complement these studies with additional informa-MATERIALS AND METHODS tion on the effect of other antitumor drugs on specific genes, Protein extracts and drugs solutions. HeLa cell nuclear and in particular on c-myc, which plays a crucial role in malig-extracts were purchased from Promega; the protein concentranant cell differentiation.
tion was between 3.6Ϫ8.3 µg/ml depending on the lot used. Pure We have sought to verify the notion that some drugs that Sp1 transcription factor was obtained from Promega. Actinomybind specifically to GϩC-rich DNA might achieve their chemo-cin D (Serva) and elsamicin A (a gift of Dr A. M. Casazza, Bristol-Myers Squibb) were freshly prepared as 250 µM stock periments. myc1 plasmid, which contains the SmaIϪSstI fragment of the human c-myc [18] , was kindly provided by Dr R. Ray (University of St Louis). Two restriction fragments from this plasmid were purified, SmaIϪXhoI to create pVP1 and XhoIϪNaeI to create pVP2, and inserted between the SmaIϪSalI sites of pBluescribe (Stratagene), grown in Escherichia coli TG1 and purified using CsCl and standard protocols. Hence, the pVP1 plasmid contains, in its SmaIϪXhoI fragment, the c-myc region from Ϫ110 to ϩ68, including the P1 initiation site (fragment SX, see Fig. 1) ; while pVP2 contains, in its XhoIϪNaeI fragment, the c-myc region from ϩ68 to ϩ212 including the P2 initiation site (fragment XN, see Fig. 1 ). DNA fragments (SX and XN) to be used in the gel retardation (band-shift) and footprinting assays were prepared by digestion with EcoRI and HindIII followed by labeling at their 3′-ends using [A-32 P]dATP and the Klenow enzyme. The fragments were further separated from the remainder of the plasmids by running on a non-denaturing 6% polyacrylamide gel.
A oligonucleotide containing the consensus Sp1 binding site [20] , whose sequence (upper strand) is: 5′ATTCGATCGGGGC-GGGGCGAGC3′ (purchased from Promega) was also employed to analyze the effect of the intercalating drugs on Sp1 binding. It was labelled at its 5′ ends using [γ-32 P]ATP and T4 poly- Fig. 1 . Schematic representation of the human c-myc P1 and P2 pronucleotide kinase.
moters. The putative Sp1 binding site, as well as the P1 and P2 start Gel retardation assays. The gel retardation (band shift) sites, are indicated (top). The indicated restriction enzymes were used assays were performed as described elsewhere [18] with a minor to generate the two fragments : SX (SmaIϪXhoI) and XN (XhoIϪNaeI).
The lower part displays the nucleotide sequences of the upper strand of modification : the binding buffer contained 2% glycerol and these restriction fragments.
0.02% Nonidet P-40 (Sigma). In reactions containing actinomycin or elsamicin, the DNA fragments were incubated with different concentrations (see legends to figures) of the drugs before 0.2 mM EDTA, 2% poly(ethyleneglycol)8000 (Sigma), 300 µM the addition of the different amounts of protein extract, except each of ATP, CTP and GTP, 1 µM UTP and 20 µCi [A-32 P]UTP, where otherwise noted. A typical reaction contained 4Ϫ12 µg in the presence of the amounts of actinomycin D or elsamicin A HeLa extract or 25 ng pure Sp1 protein and 1500Ϫ3000 cpm indicated in the legend to Fig. 8 . Transcription was allowed to (about 1.5 nmol in bp) of end-labelled DNA or oligonucleotide, proceed for 60 min at 30°C and the samples were phenol-exin the presence of 1Ϫ3 µg poly[d(I-C)] (Boehringer Mannheim).
tracted before gel loading. Transcription using HeLa whole The samples were analyzed on 4.5 % non-denaturing polyacrylnuclear extracts, in either the presence or absence of additional amide gels containing 45 mM Tris/borate, 1 mM EDTA pH 8.3.
Sp1 transcription factor (25 ng pure protein), renders two tranAfter running at low voltage (12 V/cm), the gels were soaked in scripts of 348 nucleotides (P1 promoter) and 187 nucleotides distilled water, dried under vacuum and subjected to autoradiog-(P2 promoter). In the transcription experiments an internal stanraphy. Quantitative analysis of the complex formation was perdard for recovery and gel loading was used (a 230-nucleotide formed with a Molecular Dynamics computing densitometer RNA kindly provided by Dr J. Bernués). Transcripts were anausing the ImageQuant 3.2 software. Each gel track, from four lyzed by high-voltage electrophoresis in 90 mM Tris/borate, independent experiments, was normalized with respect to the 2 mM EDTA pH 8.3 using 8 % polyacrylamide gels containing total amount of loaded radioactivity and represented as the mean 7 M urea. After running, the gels were soaked in distilled water, value Ϯ SD. dried under vacuum and the bands were observed by autoradiogDNase I footprinting. Samples containing incubated comraphy. The relative amounts of transcripts from both promoters, plexes of the end-labelled SX or XN fragments of the human cin the presence or absence of drugs, was quantified using a Momyc (3000 cpm, around 10 pmol in bp) and different concentralecular Dynamics computing densitometer. tions of actinomycin, or elsamicin, both in the presence and the absence of pure Sp1 transcription factor, at the concentrations stated in the legend of Fig. 7 , were digested with DNase I (Boeh-RESULTS ringer Mannheim) at a final concentration of 0.01 U/ml for 2 min at 25°C, and the reaction stopped by adding a solution
The influence of actinomycin D and elsamicin A on the containing 85% formamide 10 mM EDTA and 0.02% bromo-binding of protein factors, from nuclear HeLa extracts, to the phenol blue. Samples were heated at 95°C for 2 min prior to human (Ϫ110 to ϩ 212) c-myc promoter region was examined electrophoresis. The footprints were resolved by high-voltage using the gel retardation technique on two restrictions fragments electrophoresis in 90 mM Tris/borate, 2 mM EDTA pH 8.3 using (designated SX and XN, see Fig. 1 ), which contain the P1 and 6% or 8% polyacrylamide gels containing 8 M urea, together P2 promoters respectively together with the surrounding regions. with a dimethylsulphate-piperidine marker specific for guanine. These two DNA fragments were used to identify specific protein After running, the gels were soaked in distilled water, dried un-complexes as well as their sensitivity to the intercalating ligands der vacuum and the bands were observed by autoradiography.
actinomycin D and elsamicin A. In vitro transcription. The effect of actinomycin and elsamicin on the transcription of the human c-myc P1 and P2 promot-Actinomycin D and elsamicin A bind differentially to the P2 promoter of c-myc, and compete with protein factors for ers was measured using SmaI-linearized pGEMmyc1 plasmid digested with FokI. Run-off transcription assays in vitro were their binding sites. Fig. 2 shows a gel retardation experiment using the XN restriction fragment of c-myc, whose sequence is performed in a final volume of 25 µl and contained 30 mM Hepes pH 7.9, 7 mM MgCl 2 , 5 µM ZnSO 4 , 1 mM dithiothreitol, displayed in Fig. 1 . Four different complexes were observed such binding sites, the detection of a different number of proteinϪDNA interactions might originate from the different protein composition or stability of the HeLa nuclear extracts, since two different preparations containing the same amount of pro-elsamicin and actinomycin in a concentration-dependent manner. teins do not necessarily contain the same number of active pro-All the complexes were observed in the protein-DNA control tein factors. In any case, the behavior of the different complexes experiment (lanes 3 and 9) whereas they were not observed in in the presence of elsamicin and actinomycin was consistent the control of DNA alone (lane 1). The rapidly migrating prowith the binding of these drugs to GϩC-rich regions [10, 11] as tein-DNA complex, named A5, was clearly dissociated by actiit is in the experiments with mithramicin [18] . Notwithstanding, nomycin D at concentrations above 15 µM, while it remained there were differences in the concentration dependence of the quite insensitive to elsamicin up to the same concentration. The inhibition by the three drugs which may have arisen from a more presence of actinomycin produced a diminution in the intensity pronounced effect of the intercalators on DNA structure, or the of the A2 and A4 complexes in a concentration-dependent manrespective binding constants of the intercalating ligands.
ner. The incubation of the labelled DNA with the protein extract and either actinomycin D or elsamicin A added simultaneously also resulted in the inhibition of most of the DNA-protein comAt some concentrations elsamicin A might relatively enhance the binding of Sp1 protein factor to the P1 promoter of c-plexes (results not shown). Elsamicin A produced a relative increase of the A4 band at concentrations between 5Ϫ15 µM myc. A band shift analysis of the SX fragment, which contains the P1 start site, is displayed in Fig. 3A . At least six different (lanes 10 and 11), although the shifted band of the complex was always less intense than in the absence of the drug (compare protein-DNA complexes were detected when this restriction fragment was used under the experimental conditions described lanes 8 and 11 in Fig. 3 A) . At higher amounts of elsamicin a concentration-dependent disassociation of the DNA-protein in Materials and Methods. They were differentially sensitive to electrophoretic band in experiments performed with a labelled oligonucleotide containing a unique Sp1 binding site (Fig. 5) .
To seek new insight into the effect of actinomycin D and complex occurred as for actinomycin. The behavior of the A4 protein-DNA complex was reasonably reproducible in four inde-elsamicin A on the binding of Sp1 to its recognition site, we performed band-shift experiments with pure Sp1 protein on both pendent experiments. The plot in Fig. 3 B shows a quantitative analysis of the complex formation in these experiments. The the oligonucleotide (5′-ATTCGATCGGGGCGGGGCGAGC-3′, as a double strand) and the SX fragment that contains the putainterference of elsamicin and actinomycin on the formation of the A4 complex was determined from densitometric scans (see tive Sp1 binding site [20] in the c-myc promoter. Illustrated in Fig. 5 are the effects of different drug concentrations on the Materials and Methods). The dose/response curves in Fig. 3 B compare drug-treated samples with those obtained in the absence binding of Sp1 to the oligonucleotide containing its consensus sequence. The retarded electrophoretic band, which corresponds of any drug. They substantiate, within experimental error, the enhancement of the A4 band due to the binding of elsamicin, to the analyzed DNA-protein complex (lane 2 in Fig. 5 ), was sensitive to both actinomycin and elsamicin in a concentrationafter a previous decay. A further probe of this enhancement was obtained using pure protein (see below). dependent manner as detected by a titration of the previously formed protein-DNA complex using increasing amounts of actiTo evaluate the effectiveness of both drugs as inhibitors of DNA-protein complex formation, we established conditions of nomycin D (lanes 5Ϫ7) or elsamicin A (lanes 8Ϫ10). 6 µM actinomycin produced more than 90% inhibition of the DNA comthe assay to maximize complex formation. The temperature for incubation and electrophoresis were optimized to enhance the plex, while at the same concentration, or even at smaller ones, elsamicin completely prevented the formation of an Sp1-oligo stability of the DNA-protein complexes (see Materials and Methods). Due to the peculiar behavior of complex A4, we at-complex. These results agree with a competition between the two drugs, which are GϩC sequence-selective binding ligands tempted to identify the relationship between this particular band and some putative protein factors that have been described to [10, 23] , and the purified Sp1 protein factor binding to the promoter regulatory element containing a GϩC-rich tract. bind to this region of c-myc [2] . Fig. 4 shows a competition experiment between increased amounts of an unlabelled oligoAt first sight, the results obtained with elsamicin A (Fig. 5 ), seem to be at variance with a the relative increase of the comnucleotide, which contains the consensus sequence for Sp1 binding [20] , and the SX end-labelled fragment. One of the radio-plex that was observed when total HeLa extract and the SX restriction fragment described above were employed (Fig. 3) . In active bands, which appears to be the same as complex A4 (cf. Figs 3A and 4) , clearly decreased in the presence of the unla-order to investigate the modulation of Sp1 binding to the c-myc promoter by elsamicin A, and to gain further information on the belled competing oligonucleotide while the intensity of the other bands remained practically unaltered. This led us to identify the effect of some antitumor antibiotics on the promoter region of c-myc, we also performed experiments with purified human Sp1 band, the intensity of which was modulated in direct proportion to the amount of elsamicin added, as produced by Sp1 binding transcription factor and the SX fragment. In Fig. 6 the Sp1-DNA electrophoretic band was sensitive to actinomycin D with con-(lanes 10Ϫ13 in Fig. 3A) . A putative Sp1 binding site is located upstream the P1 promoter of c-myc (see Fig. 1 ). It consists of centrations of around 5 µM preventing the formation of DNAprotein complexes. However, while Sp1-DNA complex formatwo overlapping Sp1 binding sites, which can bind either a single Sp1 (giving the electrophoretic band that runs ahead) or tion seemed to be fairly blocked around 1.5 µM elsamicin A (Fig. 6 B, lane 6) , at higher concentrations (lanes 7Ϫ9) the a slowly migrating band due to the binding of two Sp1 mole- electrophoretic band increased slightly, in agreement with the observations using total nuclear HeLa extract described above (compare Figs 3 and 6B) . There is also a clear effect on the slowly migrating band, which would correspond to the binding of two Sp1 molecules as described above. When higher concentrations (around 15 µM) were used there was an inhibition of the complex formation. These experiments were also performed using different concentrations of elsamicin and the results were unambiguously reproducible. In any case, the DNA concentration in the band shifts was about 1.5 nmol (in bp), so that there was a molar excess of both purified Sp1 and drug molecules. As a result, under our experimental conditions, the amount of drug that can block (or enhance) the binding of the transcription factor to DNA (or compete for the GϩC-rich zones in DNA) was limited by the equilibrium binding constant of the reaction rather than by the drug/DNA stoichiometric ratio.
Footprinting analysis showed that Sp1 and elsamicin A can compete for their overlapping binding sites. DNase I footprinting experiments were performed to characterize binding of the pure Sp1 protein to the P1 promoter of c-myc, in the presence and absence of actinomycin and elsamicin. By using this approach, it is feasible to assess the overlapping binding sites of Sp1 and either actinomycin or elsamicin A to the c-myc P1 promoter. In all respects, binding of these drugs to the SX restriction fragment, in the absence of the protein factor, produced a footprinting pattern (Fig. 7) which resembled those obtained for these antibiotics on other DNA fragments [10, 11] . The reactions containing Sp1 showed a clear protection in a wide region of the P1 promoter. The presence of 5 µM actinomycin D or elsamicin A produced a clear footprint in the region which overlapped the Sp1 footprint. We consider that either actinomycin or elsami- Fig. 1) but not P2. The densitometric profiles used to generate the plot Lane 1, a size marker (end-labelled HinfI digest of X174 DNA) used were corrected for any gel loading artifact using the band (marker) indito locate the transcripts; lane 2, transcripts from the c-myc P1 and P2 cated by an asterisk in Fig. 8 . The transcripts obtained in the presence promoters (control); lane 3, transcripts obtained using whole HeLa exof 1 µM actinomycin D (lane 5 in Fig. 8) were not considered in this tract plus added pure Sp1 (25 ng); lanes 4Ϫ6, effect of increasing quantitative analysis since the sample was deemed to be unevenly loadamounts of actinomycin D (ACTD; 0.5, 1, 5 µM) on the run-off traned. scription; lanes 7Ϫ9, effect of increasing amounts of elsamicin A (ELSA ; 0.5, 1, 5 µM) on the run-off transcription. Note that in these transcription experiments an internal standard for recovery and gel loading was used (indicated by an asterisk).
ing site in the c-myc promoter (see Fig. 1 ). Actinomycin D strongly inhibited the transcription from P1 at all the concentrafootprinting studies, we did not find any symptom of increased tions tested (Fig. 8, lanes 4Ϫ6) while transcription from the P2 binding of Sp1 by added elsamicin, as described in the band-remains almost unaltered (lane 5 in Fig. 8 should not be taken shift studies (Figs 3Ϫ6) or the transcription assays in vitro, de-in consideration at this point since it seems to show an unevenly scribed below; undigested material is obviously difficult to ob-loaded sample). In the presence of 0.5 µM elsamicin, the transerve in a region that is already protected from DNase I cleav-scription was active from both the P1 and the P2 start sites (lane age, though the phenomenon might exist. In Fig. 7, the differ-7) . From P1 it even appeared to be fairly enhanced at concentraences between the DNase I cleavage enhancements in lanes 2 tions around 1 µM. Higher concentrations of elsamicin were re-(elsamicin ϩ Sp1) and 7 (actinomycin ϩ Sp1) support this inter-quired to completely inhibit transcription from P1. Fig. 9 shows pretation. An undigested region at the 3′ site of the c-myc P1 a quantitative analysis of the transcription from P1 and P2 propromoter (upper part of the gel) is observed in the presence of moters in which the amount of transcription has been normalized elsamicin A, or mithramycin [18], but not actinomycin D. It may using a standard for recovery and loading (indicated with an correspond, at least in part, to a distortion of the DNA structure asterisk in Fig. 8 ). The P2 transcript was clearly enhanced in the after Sp1 binding, since Sp1 binding can induce significant presence of 5 µM elsamicin while transcription from P1 was structural distortions at the 3′ site of GϩC-rich regions [24] . It strongly inhibited (Figs 8 and 9 ). These results are consistent is worth mentioning that this region contains the TATA box of with the general inhibition, by actinomycin D, of c-myc tran-P1 (see Fig. 1 ), which does not coincide with a preferred binding scription from the P1 promoter in a concentration-dependent site for the drugs studied here. manner. They also agree with the relative increment of Sp1 binding in the presence of some concentrations of elsamicin A, deElsamicin A changes the affinity of Sp1 protein for the P1 scribed in the band-shift assays and the correct assembly of the promoter while it can either inhibit or enhance the tran-initiation complex on the P1 promoter at low concentrations of scription from P2 c-myc promoter. To detect the effect of actielsamicin (1 µM). These might result in the maintenance of trannomycin D and elsamicin A on the transcription activity from scription levels and a slight increase in the yield of total tranthe P1 and P2 promoters of c-myc in vitro, we undertook a runscript formed from the P1 start site (see the quantitative analysis off transcription assay using the pGEMmyc1 plasmid (see Matein Fig. 9 ) but not from the P2 start site, which is further from rials and Methods). P1 and P2 transcripts (348 and 187 nucleothe Sp1 binding site than the P1 promoter [2] . Surprisingly, once tides) are clearly visible in the control (no drug added, Fig. 8 , P1 is inhibited (Fig. 8, lane 9) there is a manifest increase in lanes 2 and 3). Lane 3 shows the result of the trancription using transcript yield from the P2 promoter. Tentatively, we suggest HeLa extract plus added Sp1 protein (25 ng) to check the effect that this situation arises from a redistribution of some basal of elsamicin A and actinomycin D on its binding through the trans-acting factors due to the stronger binding of the drug in a indirect effect on transcription of the c-myc promoter by whole region close to P1. Some effects of drugs in the relative formaHeLa extract. Lane 3 shows that adding pure Sp1 to a HeLa tion of multimeric protein complexes have been described, as for extract (which already contains Sp1) produced an enhancement example some intercalators that affect the interaction between a of the amount of transcript from P1 but not from P2 promoter, as would be expected from the relative location of the Sp1 bind-growth response factor and the TATA-box binding protein [25] .
DISCUSSION
teristics of the c-myc P1 promoter or elsamicin A. However, since we added some pure Sp1 in the run-off experiments, it was While, in general, the major groove of DNA is recognized unambiguously established that the changes in the yield of RNA by many, but not all, trans-acting protein factors, the minor from P1 were intimately related to the levels of Sp1 binding to groove is employed by several drugs, including many intercalat-the P1 promoter region (see the quantitative analysis in Fig. 9 ). ing agents which are known to exert antitumor activity. The ex-At the same time, there was a general inhibition of the transcripperimental approaches presented in this article indicate that two tion due to the binding of the drugs to other CϩG-rich regions. such intercalators, actinomycin D and elsamicin A, might induce Several lines of evidence also show that elsamicin and actinoa specific release of some proteins which selectively bind to the mycin might behave differentially in transcription from phage human c-myc promoter. Hence, it is feasible to inhibit the bind-genes while still acting as transcription inhibitors [16] . The efing of regulatory proteins to DNA using small ligands [26, 27] . fects of actinomycin and elsamicin are not due to their direct This effect may be responsible for the differential modulation of interaction with the Sp1 protein alone, as indicated by incubating the transcription of a particular gene by intercalating agents drug and protein together first (details not reported).
(c-myc should be considered an example).
In the run-off transcription experiments using human c-myc By exploring the band-shift assays (Figs 2 to 6 ) and the (Fig. 8) , a slight increment of transcripts from P1 at 1 µM elsamDNase I footprinting (Fig. 7) , we can observe several DNA-pro-icin is evident (after inhibition at lower concentrations), in tein complexes that can be completely inhibited or/and dissoci-agreement with the effect mediated through Sp1 recognition of ated. The results presented in this article accord with the view its consensus sequence observed in the band-shift assays. Neverthat low-molecular-mass ligands are able to displace proteins theless, the drug somewhat retains the transcription to a level bound to DNA [25Ϫ28] . A possible explanation is that the com-similar to that the transcription obtained using HeLa extract petition observed is caused by a change in the local DNA con-alone, but without reaching the amounts for the HeLaϩSp1 formation. This may be mediated by the unwinding of the poly-(lanes 2 and 3 in Fig. 8 ). It is likely that the binding of elsamicin nucleotide induced by the intercalation. Nevertheless, it is worth to other CϩG-rich sites in the promoter acts as an inhibitor of noting that minor-groove binding ligands, which are considered transcription, as observed with actinomycin (Fig. 8, lanes 4Ϫ6) . to distort DNA to a lesser extent, can also inhibit the formation Hence, the effect on Sp1 binding is partially masked, yet it is of DNA-protein complexes [22, 28] .
quantitatively evident in Fig. 9 . The abilities of small ligands to Experiments using pure Sp1, and either the P1 promoter or both augment and arrest transcription by RNA polymerase II in a consensus oligonucleotide, indicate that actinomycin D and a concentration-dependent fashion does not seem to be a pecuelsamicin A overlap the Sp1 binding site, thus preventing protein liarity of the drugs and/or promoters used in this article, since binding (at any actinomycin concentration and relatively high the ability of some intercalating drugs as well as minor groove concentrations of elsamicin). Under certain concentration-de-binders to enhance and/or impede RNA elongation has been dependent conditions, the protein binding to the preferred sequence scribed elsewhere [19, 28, 29] . Notwithstanding, with elsamicin is maintained and sometimes it appears to be relatively enhanced the inhibition of the transcription from P1 was concomitant with in the vicinity of the P1 promoter. This enhancement is not ob-the increase in transcript yield from P2, which might be exserved when Sp1 is bound to a synthetic oligonucleotide that plained by considering that the some protein factors released lacks the flanking sequences in the c-myc promoter. Since from the P1 promoter bind to the P2 promoter, thus activating DNase I footprinting establishes that both drugs bind preferen-the initiation from the P2 start site (Fig. 8, lane 9, and Fig. 9 ). tially to CϩG-rich regions in DNA [10, 11] including the c-myc Nevertheless, our results point out the occurrence of this dual promoters (see Fig. 7 ), the relative enhancement in the Sp1-effect in the transcription of an oncogene in the presence of DNA complex in Figs 3 and 6 (in the presence of some concen-clinically useful drugs under physiologically relevant concentratrations of elsamicin, but not in the presence of any concentra-tions. tion of actinomycin) deserves further discussion. We tentatively So far as our results go, it seems likely that the concentraconsider that elsamicin A intercalates at DNA regions located tion-dependent response of c-myc promoter to elsamicin A is within or in the vicinity of the Sp1 binding site using the unoc-mediated by changes in the affinity of Sp1. The concentrations cupied minor groove and changing DNA to a more-favored con-of elsamicin required to observe the relative enhancement of formation for Sp1 binding, while actinomycin might occupy all protein binding (Fig. 3) or to increase the transcription yield the CϩG-rich regions and perhaps other weaker binding sites (Fig. 8) are fairly different. They possibly reflect the distinct ex- [14] , thus making some of the DNA-protein complexes more perimental conditions in the band-shift and run-off transcription sensitive than others. The binding of elsamicin is somewhat experiments. RNA polymerase II needs to read through natural driven by the flanking sequences since the phenomenon is not pause sites, in which the polymerase proceeds slowly [7, 30] . observed on the consensus oligonucleotide (Figs. 5 and 6 ). The Elsamicin might act by allowing these pauses to be overridden. conformational change produced by elsamicin binding could This explanation is consistent with the role assigned to the levels increase the affinity constant of the Sp1 protein for its consensus of Sp1 in eliminating the promoter proximal pausing of RNA sequence. In the P1 promoter of c-myc there are two overlapping polymerase in c-myc [7] . A direct link between the capacity of sequences with eight bases identical with the consensus se-elsamicin to modulate c-myc expression and to influence biologquence [2, 18] . The ability of elsamicin A to form a ternary ical processes will require further experiments in vivo. The recomplex, with Sp1 and the P1 promoter DNA, may lead to the sults described here represent a new step towards the design of stability of the protein-DNA complex at moderate drug concen-such experiments. trations, but not at higher ones. The run-off transcription experiments (Figs 8 and 9 ) agree with such an interpretation. There
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